Back to Agenda
Digital Health : What is the Landscape Looking like for Medicines?
Session Chair(s)
Chris Walker, MSc
VP, Head of Regulatory Affairs (EU,LATAM,MiddleEast,Africa,CAN)
Amgen, United Kingdom
The advent of Digital is set to revolutionize healthcare establishing new technologies and data insights that deliver greater value to healthcare systems, enhancing clinical decision making and ultimately improving outcomes for patients.This session will provide an overview of the current state of play of policy and regulatory developments in Europe , that medicines developers and digital technology providers for the pharma sector should be aware of .
Learning Objective : Understand the most recent external developments in the area of Digital Health . Analyse the existing and upcoming initiatives from different stakeholders in Digital health and their relevance to business activities
Speaker(s)
Digital Biomarkers – Case Study
Christian Gossens, PhD
F. Hoffmann-La Roche Ltd., Switzerland
Global Area Head, Digital Biomarker Informatics
New Technologies and New Approaches to Involve Patients to Improve Medicinal Product Information
Gesine Bejeuhr, PharmD
Bayer AG, Germany
Pediatric Regulatory Leader
The Regulator's View on the Need to Regulate and Challenges to Keep Pace with Technology Development
Marisa Papaluca-Amati, MD
European Medicines Agency, Netherlands
Marisa Papaluca-Amati, Scientific Committees Regulatory Science Strategy, Europe
Panel Discussion
Ernst Hafen
Institute Molecular Systems Biology, ETH, Switzerland
Professor
Have an account?